Purpose This study evaluated the cytotoxic eVects of imexon (NSC-714597) in tumor cells when combined with a broad panel of chemotherapeutic drugs. Methods The sulforhodamine B (SRB) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assays were used to analyze the degree of growth inhibition for the combination studies in the A375 human malignant melanoma and RPMI 8226 human multiple myeloma cell lines, respectively. Cells were continuously exposed to both drugs at a constant molar ratio for 4-5 days. Combination eVects were analyzed using the Median EVect method. Statistical signiWcance was inferred if the 95% conWdence interval for the combination interaction (C.I.) values for a particular two-drug combination did not include 1.0 (additivity). Synergy was inferred for C.I. values < 1.0 and antagonism for CI values > 1.0. Results Imexon was synergistic when combined with DNA-binding agents (cisplatin, dacarbazine, melphalan) and pyrimidine-based antimetabolites (cytarabine, Xuorouracil, gemcitabine) in both cell lines. Antagonistic combinations with imexon included methotrexate and the topoisomerase I (TOPO I) and II (TOPO II) inhibitors irinotecan, doxorubicin, mitoxantrone and etoposide. Docetaxel was synergistic with imexon in both cell lines whereas paclitaxel and Xudarabine showed a mixed result. Dexamethasone and the proteasome inhibitor bortezomib showed synergy in myeloma cells and additivity in the melanoma cells. The vinca alkaloid, vinorelbine, and the multi-targeted antifol, pemetrexed, were additive with imexon in both cell lines. Discussion The consistent synergy seen for imexon and alkylating agents may relate to the sulfhydryl-lowering eVect of imexon, which would render cells more sensitive to electrophilic species from the alkylators. The marked synergy noted with pyrimidine-based antimetabolites was unexpected and may relate to the induction of cell cycle arrest in S-phase. The strong antagonism noted for imexon with topoisomerase I and II inhibitors may be due to the eVect of imexon at increasing oxidant levels which are known to antagonize the cytotoxic eVects of topoisomerase poisons. In contrast, the synergy seen with bortezomib in myeloma cells may be related to an increase in reactive oxygen species (ROS) from both drugs. These results suggest that combinations of imexon with alkylating agents and pyrimidine-based antimetabolites are rational to pursue in therapeutic studies in vivo.
Introduction
Imexon (4-imino-1,3-diazabicyclo-[3.1.0] hexan-one) is an aziridine-based small molecule that exhibits antitumor activity in multiple myeloma and melanoma cell lines, animal tumor models, as well as in humans. It is also nonmyelosuppressive in vivo [13, 15] . Imexon has been shown to induce mitochondrial swelling and loss of mitochondrial membrane potential [16, 17] . This is associated with the accumulation of reactive oxygen species (ROS) and activation of the intrinsic pathway of apoptosis, involving caspases 3 and 9 [18] . In the recently completed phase I trial of imexon in patients with advanced cancers, the maximally tolerated dose was 875 mg/m 2 /day £ 5 days, every other week. This dose produced no myelosuppressionģ rade 3 [15] , suggesting that imexon could be combined with other myelosuppressive anticancer agents at full doses of both drugs.
The advantages of combination chemotherapy have been proven numerous times both in vitro and in vivo [21, 23, 26] . They include the ability to maximize cell death while minimizing toxicity through the use of drugs with nonoverlapping mechanisms of action and toxicities [8, 12, 26] . Therefore, the purpose of this study was to test imexon in combination with other classes of chemotherapy drugs to identify eVects that are greater than additive in vitro. Seven alkylating agents were evaluated in this study along with six antimetabolites, four topoisomerase inhibitors, three tubulin-binding agents, the proteasome inhibitor, bortezomib, and the glucocorticosteroid, dexamethasone. The results show consistent patterns of synergy, additivity and antagonism among the diVerent mechanistic classes of anticancer agents when combined with imexon.
Materials and methods

Chemicals
Imexon (NSC 714597) was obtained through a RAID grant to RTD from the National Cancer Institute. It was manufactured to GMP speciWcations by Series Laboratory Incorporated (Santa Rosa, CA). Cisplatin was obtained from Bayer Corp (Spokane, WA). Cytarabine was purchased from Bedford Laboratories (Bedford, OH); dexamethasone, chlorambucil, and mechlorethamine were purchased from Sigma (St. Louis, MO); doxorubicin was obtained from Fujisawa USA (DeerWeld, IL); and dacarbazine (DTIC) was purchased from Bayer Corp (West Haven, CT [24] . All cell lines were cultured in RPMI 1640 media (Gibco-BRL Products, Grand Island, NY) supplemented with 10% (v/v) heat-inactivated bovine calf serum (Hyclone Laboratories, Logan, UT), 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 g/ml) in a humidiWed incubator containing 5% CO 2 at 37°C.
Cytotoxicity studies
Cytotoxic drug activity was determined using standard 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) or sulforhodamine B (SRB) analysis. The drug concentrations and ratios used in the combination studies were determined from the IC 50 values of single-drug experiments in each cell line. The drug concentration ranges used for each combination study were developed by making incremental concentration changes above and below the IC 50 value for each antitumor drug as a single agent. In order to apply the Median EVect synergy calculation, the IC 50 of each antitumor agent was compared to the IC 50 value for imexon and a Wxed constant ratio was established for use in the subsequent combination drug exposure experiments. Five days after drug addition, 96-well plates containing RPMI 8226 cells were analyzed using the MTT (mitochondrial reductase) assay while plates containing A375 cells were analyzed using the SRB (protein-based) assay [41] . A Wxed constant ratio was used to allow a manageable matrix of experiments that could be applied to all classes of drugs.
Simultaneous exposure to both drugs (imexon plus one of the anticancer agents) was chosen as the test method. This was based on the fact that most chemotherapy combination regimens do not specify particular sequences of drug administration, and thus, most drugs are simultaneously present in the patient's bloodstream.
Median EVect analysis for drug combination
The combination interactions were analyzed using the median eVect principle using commercial software (CalcuSyn ® , Median EVect Program, Biosoft Corp., Ferguson, MO) [9] . This method is based on Michaelis-Menton kinetics and reduces combination eVects to a single numeric indicator, the combination index (C.I.). Synergy is inferred at C.I. values less than 1.0, additivity at C.I. values approximating 1.0 and antagonism at C.I. values greater than 1.0.
Statistical analysis
It is possible to see mixed eVects over a range of fraction-eVected values. For that reason, the diVerent C.I. values for a particular two-drug combination were analyzed statistically using the 95% conWdence interval test. Statistical signiWcance for the diVerent drug combinations was assessed by calculating the 95% conWdence interval, for the combination indexes (typically [8] [9] [10] , across a range of two-drug concentrations eVecting cell viability from 100% viability (0 fraction eVected) to 1-5% cell viability (99-95% fraction eVected). To reduce the bias from large positive combination index values, the C.I. values were Wrst transformed into their natural logarithm for calculation of the 95% conWdence intervals. Final results were then reconverted into the antilog of these values for summary reporting in Tables 1 and 2 . If the 95% conWdence interval range included 1.0, the interaction was deemed additive (the null hypothesis). Those combinations wherein the 95% C.I.s were > 1.0 were deemed antagonistic, and those < 1.0 were deemed synergistic.
Results
RPMI 8226 myeloma cell line
Several classes of anticancer agents demonstrated synergistic activity with imexon in the RPMI 8226 multiple myeloma cell line (Table 1 ). These include Wve of the seven alkylating agents tested. Alkylators which showed statistically signiWcant synergy included chlorambucil, cisplatin, dacarbazine, mechlorethamine and melphalan. Figure 1 shows the combination indices plotted as a function of the fractional cell survival for prototypical DNA-binding agent including the platinum-containing agent cisplatin, the bischloroethyl/based alkylators, melphalan and mechlorethanine, and the DNA methylating agent, dacarbazine. Two alkylating agents did not show synergy when combined with imexon in the myeloma cells: carboplatin demonstrated additivity, and mitomycin C demonstrated a mean combination index of 0.77 suggesting moderate synergy, however, the large variability precluded statistical signiWcance (95% C.I. of 0.09-2.46). Synergy was also observed for the combination of imexon with several pyrimidine-based antimetabolites, including cytarabine (Fig. 2a) , Xuorouracil ( Fig. 2d) and gemcitabine (Fig. 2c) . In contrast, Xudarabine ( Fig. 2b) and methotrexate ( Fig. 3a) were antagonistic when combined with imexon in the myeloma cells.
In contrast to the alkylating agents and the pyrimidinebased antimetabolites, consistent antagonism was noted for combinations of imexon with all four topoisomerase inhibitors tested in the myeloma cells. These include inhibitors of TOPO I such as irinotecan (Fig. 3b) and inhibitors of TOPO II such as doxorubicin (Fig. 3c) , mitoxantrone and etoposide (Fig. 3d) . Mixed results were identiWed when imexon was combined with the tubulinbinding agents: synergy was noted with docetaxel, but the paclitaxel combination was antagonistic. Additivity was observed with vinorelbine in the myeloma cell line ( Table 1) . The proteasome inhibitor, bortezomib, showed moderate synergy with imexon in the myeloma cells.
Two diVerent myeloma cell lines were evaluated with the combination of imexon and dexamethasone. The RPMI 8226 cell line exhibited additive eVects when dexamethasone was combined with imexon (Table 1) . Because this cell line is known to be relatively insensitive to glucocorticoid-induced cell death [11] , we also evaluated the combination of dexamethasone and imexon in a steroid-sensitive myeloma cell line, MM.1S. In this case, synergy was noted for the combination.
Imexon combinations in the A375 malignant melanoma cell line Overall, the Wndings were very similar to the myeloma results in the A375 malignant melanoma cell line (Table 2) . Synergy was again noted for imexon and most DNA-binding agents ( Fig. 1 and Table 2 ). Carboplatin was again only additive when combined with imexon. One striking exception was the combination of imexon and mechlorethamine (nitrogen mustard), which demonstrated marked antagonism (mean C.I. = 4.18, Table 2 ). Synergy again was noted with imexon combined with all four pyrimidine-based antimetabolites: cytarabine (Fig. 2a) , Xudarabine (Fig. 2b) , Xuorouracil (Fig. 2d) and gemcitabine (Fig. 2c) . As in the myeloma cells, pemetrexed showed only additivity, and methotrexate was antagonistic when combined with imexon (Fig. 3a) . Similarly, all of the topoisomerase inhibitors were antagonistic when combined with imexon in the melanoma cell line (Fig. 3b-d and Table 2 ). One diVerence with the melanoma cell line as compared to the myeloma cells was the Wnding that both taxanes were synergistic with imexon ( Table 2 ). The vinca alkaloid vinorelbine was again additive in the Table 2 ). The additivity of bortezomib in the melanoma cell line contrasts with the synergy seen with bortezomib seen in the 8226 myeloma cell line.
Discussion
Results of these imexon combination studies in two human tumor cell lines present a common theme. Imexon is synergistic with several anticancer drug classes including alkylating agents and pyrimidine-based antimetabolites. The results with two taxanes were mixed. Bortezomib and dexamethasone were only synergistic in the RPMI 8226 and MM.1S myeloma cell lines, respectively. In contrast, all of the topoisomerase inhibitors, including agents targeting TOPO I and TOPO II, were antagonistic when combined with imexon in both cell lines. The vinca alkaloid, vinorelbine, and the multi-targeted antifol, pemetrexed, were consistently additive when combined with imexon. The synergy noted for imexon with most of the alkylating agents tested may be due to the eVects of imexon on sulfhydryls [27] . Imexon binds to sulfur atoms in reduced thiols resulting in drug-thiol conjugates. In some cases, such as with cysteine, there is formation of a unique thiazoline intermediate [27] . Conversely, when imexon binds to glutathione (GSH) the reaction appears to proceed by the more common nucleophilic attack at the sulfur by the carbonium ion liberated from the aziridine moiety [27] . Imexon has been shown to decrease stores of reduced sulfhydryls in RPMI 8226 myeloma cells exposed to high drug concentrations in vitro [16] . Such a reduction in reduced sulfhydryls should render the cells much less able to neutralize reactive electrophilic species produced by the alkylating agents [3] . Indeed, reduced thiols are documented to be antagonists of several alkylating agents [2] [3] [4] [5] [6] . For example, dacarbazine cytotoxicity is synergistically increased when combined with the glutathione synthesis inhibitor, L-buthionine sulfoximine [43] , and exogenous thiols directly counteract the cytotoxic eVects of decarbazine in cell culture [42] . Glutathione and other sulfhydryls are also known to modulate cellular sensitivity and resistance to the platinum-containing agent, cisplatin [2, 4, 5, 36, 39] . In that regard, the consistent lack of synergy for imexon and carboplatin was striking, but may relate to the slower activation and lower thiol reactivity of carboplatin compared to cisplatin [31, 34] . The alkylating agent, melphalan, also showed synergy in both cell lines when combined with imexon. The relationship between melphalan resistance and an increase in cellular GSH has been shown in many diVerent types of cancer [3] , including RPMI 8226 myeloma cells [6] .
A glutathione-depletion mechanism likely cannot account for the consistent synergy seen with imexon and pyrimidine-based antimetabolites. Cytarabine and gemcitabine are primarily metabolized by cytidine deaminase, a ubiquitous enzyme with a known dependence on reduced sulfhydryls for proper activity [7] . However, pilot studies with gemcitabine have suggested that cytidine deaminase activity is not impaired by imexon [40] . Rather, the combined activity of imexon with antimetabolites may relate to the induction of cell cycle arrest in S-phase [16] or G 2 -phase [40] . This would allow for greater DNA incorporation of activated metabolites, leading to an enhanced cell kill. A similar cell cycle mechanism has been reported for the synergistic combination of gemcitabine with the ribonucleotide reductase inhibitor, hydroxyurea [44, 45] . Other drugs which have been reported to be synergistic with gemcitabine include pemetrexed [22] , bortezomib [30] , Xuorouracil [10] and oxaliplatin [19] . The molecular basis for these other drug interactions is not known. Several classes of drugs demonstrated antagonism when combined with imexon: the antifols, represented by methotrexate, and the topoisomerase I and II inhibitors. Methotrexate, which was antagonistic with imexon in both cell lines, is known to require reduced sulfhydryls for optimal cell uptake [32] . The markedly reduced activity of this combination in the current studies may be related to reduced intracellular drug accumulation. In contrast, the marked antagonism imexon seen in combinations of the topoisomerase inhibitors suggests that these agents may have reduced activity in the presence of increased ROS. Indeed, irreversible thiol oxidants such as maleimide and N-ethylmaleimide (NEM [29] ), can not only inhibit TOPO IIa catalytic activity but also antagonize the cytotoxic eVects of TOPO II poisons in several diVerent assays [29] . Maleimide and NEM have been shown to (1) reduce etoposide-induced DNA strand breaks, (2) prevent trapping of and isoforms and (3) reduce cytotoxicity in a colony-forming assay [29] . Indeed, maleimide, at noncytotoxic concentrations, was able to eYciently antagonize the cytotoxicity of daunorubicin, idarubicin, mitoxantrone and teniposide in four diVerent murine and human cancer cell lines in vitro [29] . These results suggest that TOPO II requires reduced redox conditions for full inhibition by well-characterized TOPO II poisons. Imexon may therefore be acting similarly to maleimide, by oxidizing SH groups and thereby blocking the stabilization of the TOPO-II DNA-cleavable complexes.
The antineoplastic drug, taxotere, was also synergistic with imexon in the melanoma and myeloma cell lines. It has been demonstrated that increased glutathione-S-transferase (GST) activity is related to a cellular resistance to taxotere and that a decrease in GST activity leads to increased taxotere activity [37] . The same changes, favoring increased expression of redox genes including GST, have been observed in the pre-treatment biopsy tissues of breast cancer patients who do not respond to docetaxel [28] . By depleting cellular GSH levels with imexon, GST activity slows, and taxotere activity may thereby increase. In contrast, paclitaxel was antagonistic in the myeloma cell line (mean C.I. = 2.19) and only moderately synergistic in the melanoma cell line (mean C.I. = 0.92). The antagonism with paclitaxel in the RPMI 8226 myeloma cells is similar to a previous study involving MCF-7 human breast adenocarcinoma cells and A549 human lung adenocarcinoma, which demonstrated that GSH depletion by BSO leads to antagonism of paclitaxel cytotoxicity [33] . No clear mechanism is known to account for the modest synergy noted for paclitaxel and imexon in the melanoma cell line.
Dexamethasone and imexon produced additive eVects in the A375 melanoma cells, additive eVects in the RPMI 8226 myeloma cells and synergy in the steroid-responsive MM.1S myeloma cells. These data suggest that inherent sensitivity to corticosteroid-induced apoptosis is required for synergy between imexon and glucocorticosteroids.
The synergy noted for the combination of imexon and bortezomib in the myeloma cell line may involve additive eVects on the generation of ROS, as bortezomib has been shown to increase ROS in tumor cells [35, 38] . Furthermore, the superoxide inhibitor, Tiron ® (disodium 4,5-dihydroxybenzene-1,3-disulfonate), has been shown to block bortezomib-induced cytotoxicity in human tumor cell lines, including melanoma cell lines [21] . Another agent which produces ROS and was shown to increase cytotoxicity from bortezomib is the nonsteroidal anti-inXammatory drug sulindac [35] . Thus, a likely mechanism for the synergy between bortezomib and imexon is increased production of ROS by both drugs.
Because simultaneous drug exposures were used in these studies, diVerent results might be obtained if diVerent sequences of drug exposure were evaluated [1] . However, true sequence speciWcity for clinical drug combinations is rare, and therefore simultaneous drug exposure probably best approximates the clinical setting of combination chemotherapy. Recent studies in SCID mice bearing human MiaPaCa2 pancreatic cancer cells have shown that the synergistic interaction between imexon and gemcitabine can be maintained when both drugs are administered concurrently on a weekly schedule, thereby obviating the need for repeated daily imexon injections. This schedule is currently being used in the phase I trial of imexon and gemcitabine, with both agents administered IV on days 1, 8 and 15 of a 4-week cycle.
The current Wndings suggest that further therapeutic studies with imexon should be aimed at combinations with at least four anticancer drug classes: (1) the alkylating agents, (2) pyrimidine-based antimetabolites, (3) taxotere and (4) bortezomib. Imexon combinations with topoisomerase I and II inhibitors and combinations with methotrexate were consistently antagonistic and should be avoided. Based on these Wndings, two phase I trials are currently underway with imexon in patients with advanced malignancies: a combination of imexon with gemcitabine in metastatic pancreatic cancer and imexon with dacarbazine in patients with metastatic malignant melanoma.
